Manipal Health IPO stumbles with 15% day-one subscription
Manipal Health Enterprises' ₹9,275 crore public offering saw a tepid 15% subscription on its opening day, underscoring cautious investor sentiment toward high-valued Indian healthcare assets.
Manipal Health Enterprises opened its ₹9,275 crore initial public offering on Wednesday to a muted reception, achieving just 15% overall subscription by the end of the first session. Bids totalled 1.31 crore shares against the 8.66 crore on offer, reflecting hesitant demand across major investor categories.
The lacklustre response was broad-based, with qualified institutional buyers covering only 15% of their allotted portion and non-institutional investors picking up just 8%. Retail investors showed marginally more interest, booking 27% of their quota, while employees subscribed 95% of their reserved shares.
The offering comprises a fresh equity issue worth ₹8,000 crore and an offer for sale of 2.16 crore shares worth ₹1,275.2 crore. The OFS component was halved from the 4.32 crore shares originally outlined in the draft red herring prospectus filed in March 2026. This structural adjustment signals that the company and its selling shareholders are aware of fragile market conditions, though it has done little to spur immediate demand.
Ahead of the public subscription, the hospital chain secured ₹4,167 crore from anchor investors, including the Abu Dhabi Investment Authority and Allianz Global Investors Fund. The OFS allows promoters like Imperius Healthcare Investments and Manipal Education and Medical Group India, alongside backers such as TPG SG Magazine and Novo Holdings Invest Asia, to reduce their holdings.
Backed by Temasek and Dr. Ranjan Pai, Manipal operates 49 hospitals across more than 24 cities. It ranks as India's largest multi-specialty network by bed capacity with over 12,600 operational beds, and is the second-largest chain by facility count. Capital allocation from the IPO, however, is heavily skewed toward balance sheet repair rather than funding new capacity.
The company will direct ₹5,378 crore of the fresh issue proceeds to repay borrowings, while allocating ₹574 crore to acquire a minority stake in its step-down subsidiary, Sahyadri Hospitals. The remainder is marked for general corporate purposes.
The tepid primary market response suggests investors are weighing this deleveraging focus against the company's dominant market position. This dynamic appears to be capping the valuation premium, with the grey market premium standing at just ₹10 per share. That implies a marginal 1.7% listing premium over the upper price band of ₹590.
Shares are scheduled to begin trading on the BSE and NSE on Wednesday, August 5, following allotment finalisation on August 3.
